KING OF PRUSSIA, Penn. / GOLDEN, Colo. – August 19, 2014 – PharmaJet® Inc., the developer of a needle-free injection technology to administer medications and vaccines to patients, and bioCSL Inc., the maker of AFLURIA® (Influenza Vaccine) today announced the U.S. Food and Drug Administration (FDA) has approved the PharmaJet
Read more
GOLDEN, Colo. – Feb. 22, 2013 – PharmaJet Inc. has entered into a collaboration agreement with CureVac GmbH for delivery of CureVac’s mRNA-based vaccine portfolio including targets in oncology and infectious diseases, using the PharmaJet needle-free jet injector platform.
Read more
GOLDEN, Colo. – Feb. 20, 2013 – PharmaJet Inc. has become the first and only needle-free injection company to receive Performance, Quality and Safety (PQS) pre-qualified certification from the World Health Organization (WHO).
Read more
GOLDEN, Colo. ‐ Nov. 29, 2012 – PharmaJet Inc. has entered into a collaboration with CSL Limited to enable Afluria® influenza vaccine to be delivered with the PharmaJet Stratis® needle‐free jet injector, as soon as the 2013‐2014 flu season.
Read more
GOLDEN, Colo. – March 22, 2011 – The U.S. Food and Drug Administration (FDA) has awarded PharmaJet 510(k) clearance to market a 0.1mL Intradermal (ID) Needle-free Injection System.
Read more
CDC Awards Contract to PharmaJet® for Development of Needle‐Free Intradermal Vaccine Delivery Device
GOLDEN, Colo. – Jan. 27, 2011 – The Centers for Disease Control (CDC) has awarded PharmaJet with a substantial grant to develop needle-free injection devices for intradermal (ID) vaccine delivery.
Read more